From Whispers to the Mainstage: How the Women’s Health Revolution Evolved Over 14 Years

I still remember the investor meeting that stopped me cold.

It was 2012. I was deep in fundraising mode for Wildflower, making the case that technology could transform how health plans support pregnant women and new mothers. The investor across the table (a father of three) leaned back and told me, matter-of-factly, that he had a policy of never investing in products he couldn’t personally use. He couldn’t be pregnant. Therefore, he couldn’t invest.

I walked out of that meeting equal parts incredulous and galvanized. It wasn’t just the logic; it was what it revealed about the moment we were in. Women’s health was considered a niche. A specialty. Something that applied to half the population but apparently commanded the interest of very few people with capital.

Back then, I could barely get the market to engage in serious conversations about pregnancy and childbirth, let alone topics like breastfeeding support, pelvic floor health, postpartum depression, or menopause. These weren’t just underfunded — they were barely spoken.

A Seismic Shift — 14 Years in the Making

Today, as we celebrate Wildflower’s June birthday, the landscape looks almost unrecognizable.

Women’s health has grown into a multi-billion-dollar sector, and more importantly, the very definition of what it encompasses has fundamentally expanded. The field no longer centers exclusively on reproductive anatomy. It now honors the full spectrum of how healthcare intersects with women’s lives: The unique social and emotional dimensions, the conditions that manifest differently by gender, the prevention and treatment approaches that must account for bodies and experiences that have historically been underrepresented in research.

Menopause is on the cover of mainstream magazines. Pelvic floor health is a topic at dinner tables and in boardrooms. Postpartum mental health is finally being treated as the medical reality it always was. Topics that once required careful euphemism are now spoken plainly — and that directness has itself become a form of advocacy.

Wildflower has had a front-row seat to this transformation, and in many ways, has helped drive it. When we launched, we were a focused digital solution helping health plans identify and engage high-risk pregnancies earlier. Today, we are a multi-channel, networked care platform enabling hybrid care delivery and value-based models across a broad range of women’s health needs.

Our evolution mirrors the evolution of the field itself: From a narrow clinical lens to a fuller, more human one.

Progress Has a Complicated Story

I’d be doing a disservice to the women we serve if I only told the triumphant version of this story. Even as investment in women’s health has grown, some of the most foundational metrics have moved in the wrong direction:

• Maternal mortality rates in the United States remain a national shame, particularly for Black women.

• Preterm birth rates have not meaningfully improved.

• Overall life expectancy for women has declined in recent years.

• We are watching real regulatory setbacks unfold in real time, alongside shrinking numbers of providers in critical specialties.

The cultural conversation has opened up. The capital has started flowing. But the systems — the ones that determine whether a woman in a rural county has access to an OB, or whether a new mother’s mental health crisis is caught before it escalates — those systems are still failing too many people.

Why We Stay Committed, Especially Now

The gap between the cultural moment and the clinical reality is precisely what makes this work matter. It’s also what shapes Wildflower’s commitment.

Being deeply tuned in to the evolution of women’s health — the research, the advocacy, the patient voices, the policy shifts — is not just background noise for us. It is how we build. It’s how we decide where to expand, who to partner with, and what kinds of care models to enable. It’s how we stay ahead of what women actually need, rather than what the system has historically been designed to deliver.

Fourteen years ago, an investor told me he couldn’t engage with something so far outside his own experience. We’ve spent every year since proving that premise wrong, demonstrating that investing in women’s health is not a niche bet, but one of the highest-leverage opportunities in all of healthcare.

The conversation has moved from whispers to the mainstage. But the work — the hard, systemic, unglamorous work of actually improving outcomes — is far from over. And Wildflower intends to be in it for every year to come.